Toth Financial Advisory Corp Acquires 4,762 Shares of iShares Biotechnology ETF $IBB

Toth Financial Advisory Corp lifted its holdings in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 12.7% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 42,261 shares of the financial services provider’s stock after acquiring an additional 4,762 shares during the quarter. Toth Financial Advisory Corp owned approximately 0.09% of iShares Biotechnology ETF worth $8,038,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Bank of America Corp DE grew its position in shares of iShares Biotechnology ETF by 10.8% in the 1st quarter. Bank of America Corp DE now owns 7,259,501 shares of the financial services provider’s stock worth $1,225,767,000 after buying an additional 707,343 shares during the period. Citigroup Inc. raised its holdings in iShares Biotechnology ETF by 40.9% in the fourth quarter. Citigroup Inc. now owns 5,242,688 shares of the financial services provider’s stock worth $884,808,000 after buying an additional 1,521,992 shares during the last quarter. Morgan Stanley lifted its stake in shares of iShares Biotechnology ETF by 2.5% in the fourth quarter. Morgan Stanley now owns 3,204,126 shares of the financial services provider’s stock worth $540,760,000 after buying an additional 76,978 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in shares of iShares Biotechnology ETF by 11.4% during the fourth quarter. BNP Paribas Financial Markets now owns 2,133,461 shares of the financial services provider’s stock valued at $360,064,000 after buying an additional 218,066 shares during the last quarter. Finally, Raymond James Financial Inc. grew its holdings in shares of iShares Biotechnology ETF by 286.2% during the fourth quarter. Raymond James Financial Inc. now owns 994,311 shares of the financial services provider’s stock valued at $167,810,000 after buying an additional 736,881 shares during the last quarter. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Performance

Shares of NASDAQ IBB opened at $208.95 on Friday. iShares Biotechnology ETF has a twelve month low of $137.63 and a twelve month high of $217.12. The company has a 50 day moving average of $195.01 and a 200 day moving average of $178.87.

iShares Biotechnology ETF Cuts Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, June 18th. Shareholders of record on Monday, June 15th were given a $0.0238 dividend. This represents a $0.10 dividend on an annualized basis and a yield of 0.0%. The ex-dividend date of this dividend was Monday, June 15th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.